In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy.|https://dx.doi.org/10.1101/2023.09.22.559005
When less is more: shortening the Lpp protein leads to increased vancomycin resistance in Escherichia coli.|https://dx.doi.org/10.1038/s41429-023-00658-3
A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020-2021.|https://dx.doi.org/10.1128/aac.00349-23
Evaluation of the effectiveness and safety of oral vancomycin versus placebo in the prevention of recurrence of Clostridioides difficile infection in patients under systemic antibiotic therapy: a phase III, randomised, double-blind clinical trial.|https://dx.doi.org/10.1136/bmjopen-2023-072121
Incidence and risk factors for recurrent Clostridioides difficile infection in pediatric at-risk groups in selected Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) hospitals.|https://dx.doi.org/10.1017/ice.2023.174
Clostridioides difficile Infection in Inflammatory Bowel Disease Patients: A Systematic Review of Risk Factors and Approach in Management.|https://dx.doi.org/10.7759/cureus.43134
Effectiveness of ultraviolet-C disinfection systems for reduction of multi-drug resistant organism infections in healthcare settings: A systematic review and meta-analysis.|https://dx.doi.org/10.1017/S0950268823001371
Design, Synthesis and Biological Evaluation of Novel PEG-Rakicidin B1 Hybrid as Clostridium difficile (CD) Targeted Anti-Bacterial Agent.|https://dx.doi.org/10.3390/molecules28166152
Clinical Efficacy of Fidaxomicin and Oral Metronidazole for Treating Clostridioides difficile Infection and the Associated Recurrence Rate: A Retrospective Cohort Study.|https://dx.doi.org/10.3390/antibiotics12081323
